Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Helus Pharma CEO Fireside Chat at...
Business conference participation

Helus Pharma CEO Fireside Chat at Canaccord Conference

Analysis based on 6 articles · First reported Aug 10, 2026 · Last updated Aug 10, 2026

Sentiment
0
Attention
0
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement is a routine corporate communication with minimal direct market impact. It may provide a platform for the CEO to discuss pipeline progress, potentially influencing investor sentiment modestly.

Pharmaceuticals
Event Summary

Helus Pharma, the commercial operating name of Cybin Inc., announced that its CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026. The chat will be webcast live. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions. Its lead candidate HLP003 is in Phase 3 for major depressive disorder and has received Breakthrough Therapy Designation from the United States — Food and Drug Administration. HLP004 is in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Republic of Ireland.

Key Actions
30 Helus Pharma announced participation
Entities Involved
priv
Helus Pharma
Helus Pharma is the subject of the announcement, using the conference to increase visibility among investors.
Importance 100.0 Sentiment 0.0
stock
Cybin Inc.
Cybin Inc. is the parent company operating as Helus Pharma; the event highlights its clinical programs.
Importance 90.0 Sentiment 0.0
per
Michael Halstead
As CEO, Halstead represents the company at the conference, discussing strategy and pipeline.
Importance 80.0 Sentiment 0.0
stock
Canaccord Genuity
Hosts the growth conference, providing a venue for company presentations.
Importance 60.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Granted Breakthrough Therapy Designation to HLP003, a key regulatory milestone.
Importance 40.0 Sentiment 0.0
exch
Nasdaq
Listing exchange for Helus Pharma's shares.
Importance 30.0 Sentiment 0.0
cnt
Canada
Secondary listing exchange for Helus Pharma's shares.
Importance 30.0 Sentiment 0.0
cnt
United States
One of the countries where the company operates and where the conference is held.
Importance 20.0 Sentiment 0.0
govactor
Canada — Health Canada
Mentioned as a regulator that has not evaluated the company's products.
Importance 20.0 Sentiment 0.0
cnt
United Kingdom
One of the countries where the company operates.
Importance 20.0 Sentiment 0.0
cnt
Republic of Ireland
One of the countries where the company operates.
Importance 20.0 Sentiment 0.0
Relationships
Canaccord Genuity related ↔ Nasdaq
United States — Food and Drug Administration related ↔ Nasdaq
United States — Food and Drug Administration related ↔ Canada
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ Canada — Health Canada
United States — Food and Drug Administration related ↔ United Kingdom
Nasdaq related ↔ United States
Nasdaq related ↔ United Kingdom
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
Canada related ↔ Canada — Health Canada
Canada related ↔ United Kingdom
United States related ↔ Canada — Health Canada
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
Canada — Health Canada related ↔ United Kingdom
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.